Skip to content
S1159Senate2023-2024 SessionSame asA9152

Disclose Prenatal Test Accuracy

Official title

“Requires disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities”

Sponsor James SkoufisSD-42+2 co-sponsorsAffects Health
Status
In Assembly Committee
Health
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 5 of 7

In Assembly · Health

What's happening

This bill requires clear disclosure and informational materials about the uses, limitations, and risks of non-invasive prenatal screening for chromosomal abnormalities.

Why it matters

  1. Ensures patients receive accurate information. The bill mandates that clear, plain-language disclosures about the purpose and limitations of non-invasive prenatal screenings be provided before testing, with results, and in all related materials. This helps patients and expectant parents better understand that these tests assess risk, not provide a diagnosis, and that follow-up diagnostic testing is recommended for positive results.

  2. Reduces risk of misunderstanding test results. By requiring that information about false positives, false negatives, and the need for confirmatory testing be included in written notices, the bill addresses common misconceptions that can lead to unnecessary anxiety or inappropriate decisions based on screening results alone.

  3. Standardizes informational materials statewide. The Department of Health must review and approve all patient notices, and create comprehensive, multi-language resources outlining the benefits, limitations, and regulatory status of available tests. This ensures consistency and equitable access to accurate information across healthcare providers.

  4. Supports informed decision-making in prenatal care. By referencing leading medical guidelines and specifying which tests are FDA or state approved, the bill empowers patients and providers to make choices about screenings and follow-up care based on the latest standards and evidence, while preserving the provider’s professional judgment.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Patients and potential parents

    They would receive written notices before prenatal testing, with results and in testing materials explaining screening limits and the need for confirmatory diagnostic testing after a positive result.

  • Prenatal screening manufacturers, suppliers and advertisers

    They would have to provide plainly worded, prominently displayed notices reviewed and approved by the state Health Department.

  • New York State Health Department

    It would review and approve notices and develop printable, multilingual materials explaining testing benefits, limitations, professional recommendations and approved or cleared screening tests.

  • Obstetricians, midwives, hospitals and other prenatal care providers

    They could use the state’s informational materials in prenatal care, while the bill would preserve practitioners’ ability to recommend testing based on reasonable, good-faith professional judgment.

Headline styles

Disclose Prenatal Test Accuracy

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
James Skoufis

Senator · Senate District 42

Chair, Investigations And Government Operations

History

  1. Referred to health
  2. Delivered to assembly
  3. Passed senateVote 61–0
  4. Amended on third reading 1159b
  5. Advanced to third reading
  6. 2nd report cal.
  7. 1st report cal.381
  8. Print number 1159a
  9. Amend (t) and recommit to health
  10. Referred to health
  11. Committed to rules
  12. Advanced to third reading
Show 3 earlier actions
  1. 2nd report cal.
  2. 1st report cal.244
  3. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A9152Assembly

Explain Prenatal Test Accuracy

In Assembly Committee · Health · Sponsor Amy Paulin

Impact 6 · Moderate0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

1159--B Cal. No. 381

2023-2024 Regular Sessions

IN SENATE

January 10, 2023

Introduced by Sens. SKOUFIS, THOMAS, WEBB -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- recommitted to the Committee on Health in accordance with Senate Rule 6, sec. 8 -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- reported favorably from said committee, ordered to first and second report, ordered to a third reading, amended and ordered reprinted, retaining its place in the order of third reading

AN ACT to amend the public health law, in relation to requiring disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. The public health law is amended by adding a new section 2533 to read as follows:

§ 2533. Disclosure of information concerning non-invasive prenatal screening for chromosomal abnormalities. 1. For the purposes of this section, the term "non-invasive prenatal screening" shall mean any noninvasive prenatal screening or cell free fetal DNA screening used to ascertain whether a fetus is at risk for certain chromosomal abnormalities.

2. Non-invasive prenatal screenings shall be accompanied by a written notice, provided by the entity which manufactured, supplied, or otherwise created such test or which advertised performing these prenatal screening tests, about the use of such test for screening purposes, the fact that not all high risk occurrences correspond to a positive result, the fact that not all low risk results correspond to a negative result, a clear statement indicating that non-invasive prenatal screenings are intended solely for screening purposes to assess risk of possible fetal genetic abnormalities and is not intended to be used for diagnostic purposes to determine whether such abnormalities actually exist and that

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD04085-04-4

any positive result should be followed by confirmatory diagnostic testing, and that additional follow up is recommended for all high risk screening. Such written notice shall be provided to a patient or a potential parent: (a) prior to any prenatal test; (b) with such test results; and (c) with any materials provided by the entity providing or facilitating the prenatal testing. Such written notice shall be reviewed and approved by the department. Such written notice shall be plainly worded and prominently displayed in any material presented to a patient or a potential parent about prenatal testing services.

c. Nothing contained in this section shall be construed to limit a health care practitioner licensed, certified, or authorized under title eight of the education law from recommending certain prenatal testing services according to the practitioner's reasonable and good faith professional judgment based on the facts of a patient's case.

§ 2. Section 266 of the public health law is amended by adding a new subdivision 7 to read as follows:

7. Non-invasive prenatal testing. In addition to the information provided pursuant to this section, the commissioner shall also develop comprehensive informational materials regarding the benefits and limitations of non-invasive prenatal testing, including the difference between non-invasive prenatal testing and prenatal diagnostic testing. Such information shall be posted on the website in a printable format, in multiple languages in accordance with section two hundred two-a of the executive law to allow all general hospitals, diagnostic and treatment centers, obstetricians, primary care providers, midwives, and other health care programs providing women's wellness services to provide the information to their patients as part of their prenatal care activities. The informational materials shall also include:

(a) the current recommendations on non-invasive prenatal testing made by the American College of Obstetricians and Gynecologists (ACOG), and the Society for Maternal Fetal Medicine, and the American College of Medical Genetics and Genomics (ACMG);

(b) a statement informing individuals that non-invasive prenatal testing is used for screening purposes to determine the potential for possible fetal genetic abnormalities and is not intended to determine whether or not such abnormalities exist;

(c) a statement informing individuals that non-invasive prenatal testing carries a risk of false-positive results and that any positive result should be followed up with prenatal diagnostic testing; and

(d) a list of the non-invasive screening tests that have been approved or cleared by the federal Food and Drug Administration (FDA), the New York State Clinical Laboratory Evaluation Program (CLEP), or both, and a summary of the known performance characteristics of these tests when available.

§ 3. This act shall take effect on the one hundred eightieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public health law, in relation to requiring disclo- sure of information concerning non-invasive prenatal screening for chro- mosomal abnormalities

Purpose

Requires that entities resting providing non-invasive prenatal screening for chromosomal abnormalities disclose information about the screening and what the results could mean to patients

Summary of provisions

Section 1: Amends the public health law by adding a new section 2533, requiring a disclosure of information regarding non-invasive prenatal screening for chromosomal abnormalities. It provides definitions for terms such as "non-invasive prenatal screening." States that Non-inva- sive prenatal screenings must be accompanied by a written notice, provided by the entity responsible for the test, outlining information about the purpose of the test, the limitations of results, and the recommendation for confirmatory diagnostic testing in case of a positive result. The written notice is required before the prenatal test, with test results, and with any materials related to the prenatal testing.

Section 2: Amends Section 266 of the public health law to include a new subdivision 7, mandating the commissioner of the DOH develop comprehen- sive informational materials about non-invasive prenatal testing, including its benefits and limitations.

Section 3: Sets effective date.

Justification

Knowledge is essential to empower patients to make informed decisions about their pregnancies. The proliferation of prenatal genetic testing has provided healthcare providers and prospective parents with an ever- expanding list of conditions for which a fetus can be tested early in pregnancy.

Unfortunately, recent media reports have found that testing companies are not providing doctors and patients with relevant information on the high rate of false positive outcomes when testing for statistically rare developmental conditions. In some cases, these tests have false positive rates as high as 85-90%, yet on product brochures prior to testing, and even on the test result sheets, companies describe the test results as near certain in accuracy (language such as "reliable)" "highly accu- rate," "total confidence," and "peace of mind" are included in promo- tional advertising and documentation provided by testing companies.

This bill would require testing companies to provide information about the use of such test for screening purposes, the fact that not all high risk occurrences correspond to a positive result, the fact that not all low risk results correspond to a negative result, a clear statement indicating that NIPS are intended solely for screening purposes and that any positive result should be followed by confirmatory diagnostic test- ing. Such language would be required by this bill to be understandable and easily visible when provided.

Additionally, the bill addresses the need for widespread dissemination of information about non-invasive prenatal testing. By requiring the commissioner to develop informational materials in multiple languages to post on the DOH website, the bill aims to allow a diverse population to easily access crucial information about the benefits and limitations of NIPS with a simple search online.

Legislative history

Senate

2023: S8286, Referred to Health

2021-2022: S8286, Referred to Health

Assembly

2021-2022: A9413, Referred to Health

Fiscal implications

Minimal costs to the Department of Health to be determined.

Effective date

This act shall take effect on the one hundred eightieth day after 39 it shall have become a law.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.